Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2007-12-21
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 45
- Registration Number
- NCT00578149
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
- Conditions
- Endometrial Adenosquamous CarcinomaEndometrial Clear Cell AdenocarcinomaStage IVB Uterine Corpus CancerStage IVA Uterine Corpus CancerEndometrial Mixed AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Squamous Cell CarcinomaEndometrial Undifferentiated CarcinomaRecurrent Uterine Corpus CarcinomaStage IIIA Uterine Corpus Cancer
- Interventions
- Drug: CisplatinDrug: Doxorubicin HydrochlorideBiological: FilgrastimDrug: PaclitaxelBiological: Pegfilgrastim
- First Posted Date
- 2007-12-18
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 27
- Registration Number
- NCT00575952
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Albert Einstein College of Medicine
- Target Recruit Count
- 55
- Registration Number
- NCT00574587
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma
- Conditions
- Loco-regional Esophageal Cancer
- Interventions
- Drug: BevacizumabDrug: PaclitaxelDrug: CisplatinDrug: 5-FluorouracilRadiation: Radiation TherapyProcedure: Esophagectomy
- First Posted Date
- 2007-12-11
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00570531
Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma
- Conditions
- Melanoma (Skin)
- Interventions
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2015-12-30
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 12
- Registration Number
- NCT00568451
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2016-02-10
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 2600
- Registration Number
- NCT00567554
- Locations
- 🇩🇪
Universitätsfrauenklinik Frankfurt / Main, Frankfurt / Main, Germany
Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer
- Conditions
- Head and Neck Cancer
- Interventions
- Drug: CisplatinDrug: PaclitaxelRadiation: Intensity-Modulated Radiation Therapy (IMRT) External Beam RadiationProcedure: Triple endoscopy and biopsy
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2021-11-26
- Target Recruit Count
- 11
- Registration Number
- NCT00566540
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Fallopian Tube Mucinous AdenocarcinomaOvarian Clear Cell AdenocarcinofibromaOvarian Serous AdenocarcinomaPrimary Peritoneal Undifferentiated CarcinomaUndifferentiated CarcinomaClear Cell AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaOvarian Brenner TumorOvarian Clear Cell AdenocarcinomaOvarian Transitional Cell Carcinoma
- Interventions
- Drug: CarboplatinBiological: BevacizumabDrug: DocetaxelDrug: Gemcitabine HydrochlorideOther: Laboratory Biomarker AnalysisDrug: PaclitaxelOther: Quality-of-Life Assessment
- First Posted Date
- 2007-11-30
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1052
- Registration Number
- NCT00565851
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
🇺🇸Sanford Bismarck Medical Center, Bismarck, North Dakota, United States
🇺🇸Sanford Broadway Medical Center, Fargo, North Dakota, United States
FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
- Conditions
- Malignant Pleural EffusionStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
- Interventions
- Drug: carboplatinDrug: docetaxelDrug: gemcitabine hydrochlorideDrug: paclitaxelProcedure: computed tomographyProcedure: positron emission tomographyRadiation: fludeoxyglucose F 18Other: imaging biomarker analysis
- First Posted Date
- 2007-11-28
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 55
- Registration Number
- NCT00564733
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸Harborview Medical Center, Seattle, Washington, United States
TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Small Cell Lung CancerLung Cancer
- Interventions
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 68
- Registration Number
- NCT00563784
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.